The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
Overview
Affiliations
We present novel data demonstrating that the expression of PPARγ is reduced in lung fibroblasts from black SSc-ILD patients as compared to white patients. Activating PPARγ with the agonist rosiglitazone increased the expression of MMP-1 and inhibited collagen type I in lung fibroblasts isolated from white, but not black, SSc-ILD patients. Blocking the c-Met receptor abolishes rosiglitazone's effects on collagen and MMP-1 in lung fibroblasts isolated from white SSc-ILD patients, while augmenting the expression of the c-Met receptor in fibroblasts from black SSc-ILD patients replicates the effects of rosiglitazone seen in whites. We conclude that PPARγ agonists warrant consideration as potential antifibrotic drugs in patients with SSc-ILD. Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor.
Cerro-Chiang G, Ayres M, Rivas A, Romero T, Parker S, Mastali M Sci Rep. 2023; 13(1):8645.
PMID: 37244972 PMC: 10224939. DOI: 10.1038/s41598-023-35840-y.
Serum Adiponectin, a Novel Biomarker Correlates with Skin Thickness in Systemic Sclerosis.
Leodori G, Pellicano C, Basile V, Colalillo A, Navarini L, Gigante A J Pers Med. 2022; 12(10).
PMID: 36294874 PMC: 9604668. DOI: 10.3390/jpm12101737.
Lecarpentier Y, Gourrier E, Gobert V, Vallee A Front Pediatr. 2019; 7:176.
PMID: 31131268 PMC: 6509750. DOI: 10.3389/fped.2019.00176.
Drugs and Targets in Fibrosis.
Li X, Zhu L, Wang B, Yuan M, Zhu R Front Pharmacol. 2017; 8:855.
PMID: 29218009 PMC: 5703866. DOI: 10.3389/fphar.2017.00855.
Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target.
Marangoni R, Masui Y, Fang F, Korman B, Lord G, Lee J Sci Rep. 2017; 7(1):4397.
PMID: 28667272 PMC: 5493638. DOI: 10.1038/s41598-017-04162-1.